# Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer：MetBio-GC

> **NCT07076979** · — · RECRUITING · sponsor: **Shanghai Minimally Invasive Surgery Center** · enrollment: 250 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07076979
- **Lead sponsor:** Shanghai Minimally Invasive Surgery Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-15
- **Primary completion:** 2028-07-01
- **Final completion:** 2030-07-01
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07076979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07076979, "Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer：MetBio-GC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07076979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*